We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $363M
1-Year Est. Return 34.89%
This Fund
S&P 500
This Quarter Est. Return
+9.85%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$349M
AUM Growth
+$53.4M
Cap. Flow
+$36.4M
Cap. Flow %
10.41%
Top 10 Hldgs %
7.12%
Holding
478
New
39
Increased
273
Reduced
76
Closed
38

Top Buys

Rank Stock Value
1
OXLC
Oxford Lane Capital
OXLC
+$2.36M
2
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$1.99M
3
LRCX icon
Lam Research
LRCX
+$1.97M
4
IDXX icon
Idexx Laboratories
IDXX
+$1.96M
5
TKO icon
TKO Group
TKO
+$1.96M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$1.85M
2
KKR icon
KKR & Co
KKR
+$1.62M
3
UAL icon
United Airlines
UAL
+$1.62M
4
CBRE icon
CBRE Group
CBRE
+$1.61M
5
NU icon
Nu Holdings
NU
+$1.58M

Sector Composition

Rank Sector Weight
1 Financials 33.25%
2 Healthcare 17.27%
3 Technology 14.61%
4 Industrials 8.9%
5 Consumer Discretionary 5.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYN icon
426
Dyne Therapeutics
DYN
$4.95B
$99.5K 0.03%
7,869
+1,366
+21% +$15.6K
NGNE icon
427
Neurogene
NGNE
$729M
$96.7K 0.03%
5,578
+969
+21% +$19.5K
SLNO
428
DELISTED
Soleno Therapeutics
SLNO
$95.9K 0.03%
1,419
+247
+21% +$18.3K
AVBP icon
429
ArriVent BioPharma
AVBP
$1.44B
$88.9K 0.03%
4,816
+837
+21% +$16.4K
NRIX icon
430
Nurix Therapeutics
NRIX
$2.69B
$87.9K 0.03%
9,514
+1,652
+21% +$17.2K
AUTL
431
Autolus Therapeutics
AUTL
$551M
$86.3K 0.02%
52,924
+9,188
+21% +$17.9K
MREO
432
Mereo BioPharma
MREO
$43.5M
$84.3K 0.02%
40,930
+7,105
+21% +$13.1K
TRDA icon
433
Entrada Therapeutics
TRDA
$271M
$84.1K 0.02%
14,495
+2,516
+21% +$14.7K
TECX
434
Tectonic Therapeutic
TECX
$639M
$79.6K 0.02%
5,071
+881
+21% +$18.2K
CGEM icon
435
Cullinan Oncology
CGEM
$1.18B
$75.4K 0.02%
12,714
+2,208
+21% +$16.2K
ALT icon
436
Altimmune
ALT
$593M
$60K 0.02%
15,914
+2,763
+21% +$10.7K
CAPR icon
437
Capricor Therapeutics
CAPR
$223M
$58.9K 0.02%
8,163
+1,417
+21% +$10.4K
REPL icon
438
Replimune Group
REPL
$1.15B
$48.2K 0.01%
11,511
+1,998
+21% +$12.8K
MLTX icon
439
MoonLake Immunotherapeutics
MLTX
$1.47B
$18.5K 0.01%
2,585
+449
+21% +$23.4K
AAPL icon
440
Apple
AAPL
$4.5T
– –
-6,623
Closed -$1.36M
ACGL icon
441
Arch Capital
ACGL
$33.5B
– –
-15,279
Closed -$1.39M
AFL icon
442
Aflac
AFL
$61.2B
– –
-12,839
Closed -$1.35M
BGX
443
Blackstone Long-Short Credit Income Fund
BGX
$138M
– –
-56,944
Closed -$707K
CBRE icon
444
CBRE Group
CBRE
$41.7B
– –
-11,480
Closed -$1.61M
CCIF
445
Carlyle Credit Income Fund
CCIF
$58.3M
– –
-181,994
Closed -$1.18M
CHD icon
446
Church & Dwight Co
CHD
$24.5B
– –
-13,956
Closed -$1.34M
CPRT icon
447
Copart
CPRT
$27.4B
– –
-22,755
Closed -$1.12M
CTSH icon
448
Cognizant
CTSH
$26.3B
– –
-19,203
Closed -$1.5M
ECL icon
449
Ecolab
ECL
$79.7B
– –
-5,819
Closed -$1.57M
EFR
450
Eaton Vance Senior Floating-Rate Fund
EFR
$319M
– –
-65,479
Closed -$794K
16 17
18
19 20

Similar funds

WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
HS
HighVista Strategies Boston, Massachusetts $362M AUM 230.96% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
RGC
Roberts, Glore & Co Deerfield, Illinois $364M AUM 19.54% 1-Year Est. Return

Virtus Investment Advisers's Q3 2025 Portfolio in Review

As of Q3 2025, Virtus Investment Advisers held 478 positions worth $349M, up 18% from $296M the previous quarter. Its ten largest holdings account for 7.1% of the portfolio.

Virtus Investment Advisers deployed $36.4M of net new capital in Q3 2025, opening 39 new positions and adding to 273 existing holdings. Its largest new stake was Oxford Lane Capital: 129,209 shares worth $2.19M.

By sector, the portfolio is most concentrated in Financials at 33% of assets, up from 33% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Incyte, an estimated $1.85M trimmed.

  • Virtus Investment Advisers's largest Q3 2025 buy was Oxford Lane Capital: 129,209 shares worth $2.19M.
  • Virtus Investment Advisers added most to Prospect Capital in Q3 2025, an estimated $697K increase.
  • Virtus Investment Advisers's biggest Q3 2025 reduction was Incyte, cutting an estimated $1.85M.
  • Virtus Investment Advisers fully exited KKR & Co in Q3 2025, selling an estimated $1.62M.
  • Virtus Investment Advisers's ten largest holdings make up 7.1% of its $349M portfolio in Q3 2025.
  • Virtus Investment Advisers opened 39 new positions and closed 38 in Q3 2025.
  • Virtus Investment Advisers's portfolio value rose 18% quarter-over-quarter to $349M.

Based on Virtus Investment Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.